Your browser doesn't support javascript.
loading
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.
Solomon, Isabelle; Amann, Maria; Goubier, Anne; Arce Vargas, Frederick; Zervas, Dimitrios; Qing, Chen; Henry, Jake Y; Ghorani, Ehsan; Akarca, Ayse U; Marafioti, Teresa; Sledzinska, Anna; Werner Sunderland, Mariana; Franz Demane, Dafne; Clancy, Joanne Ruth; Georgiou, Andrew; Salimu, Josephine; Merchiers, Pascal; Brown, Mark Adrian; Flury, Reto; Eckmann, Jan; Murgia, Claudio; Sam, Johannes; Jacobsen, Bjoern; Marrer-Berger, Estelle; Boetsch, Christophe; Belli, Sara; Leibrock, Lea; Benz, Joerg; Koll, Hans; Sutmuller, Roger; Peggs, Karl S; Quezada, Sergio A.
Afiliação
  • Solomon I; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
  • Amann M; Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland. Maria.Amann@Roche.com.
  • Goubier A; Tusk Therapeutics Ltd., Stevenage Bioscience Catalyst, Stevenage, UK.
  • Arce Vargas F; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
  • Zervas D; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
  • Qing C; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
  • Henry JY; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
  • Ghorani E; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
  • Akarca AU; Department of Cellular Pathology, University College London Hospital, London, UK.
  • Marafioti T; Department of Cellular Pathology, University College London Hospital, London, UK.
  • Sledzinska A; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
  • Werner Sunderland M; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
  • Franz Demane D; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
  • Clancy JR; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
  • Georgiou A; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
  • Salimu J; Tusk Therapeutics Ltd., Stevenage Bioscience Catalyst, Stevenage, UK.
  • Merchiers P; Tusk Therapeutics Ltd., Stevenage Bioscience Catalyst, Stevenage, UK.
  • Brown MA; Tusk Therapeutics Ltd., Stevenage Bioscience Catalyst, Stevenage, UK.
  • Flury R; Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland.
  • Eckmann J; Roche Innovation Center Munich, Roche Pharmaceutical Research and Development (pRED), Penzberg, Germany.
  • Murgia C; Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland.
  • Sam J; Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland.
  • Jacobsen B; Roche Innovation Center Basel, Roche Pharmaceutical Research and Development (pRED), Basel, Switzerland.
  • Marrer-Berger E; Roche Innovation Center Basel, Roche Pharmaceutical Research and Development (pRED), Basel, Switzerland.
  • Boetsch C; Roche Innovation Center Basel, Roche Pharmaceutical Research and Development (pRED), Basel, Switzerland.
  • Belli S; Roche Innovation Center Basel, Roche Pharmaceutical Research and Development (pRED), Basel, Switzerland.
  • Leibrock L; Roche Innovation Center Basel, Roche Pharmaceutical Research and Development (pRED), Basel, Switzerland.
  • Benz J; Roche Innovation Center Basel, Roche Pharmaceutical Research and Development (pRED), Basel, Switzerland.
  • Koll H; Roche Innovation Center Munich, Roche Pharmaceutical Research and Development (pRED), Penzberg, Germany.
  • Sutmuller R; Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland.
  • Peggs KS; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK. k.peggs@ucl.ac.uk.
  • Quezada SA; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK. s.quezada@ucl.ac.uk.
Nat Cancer ; 1(12): 1153-1166, 2020 12.
Article em En | MEDLINE | ID: mdl-33644766
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interleucina-2 / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Nat Cancer Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interleucina-2 / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Nat Cancer Ano de publicação: 2020 Tipo de documento: Article